Bristol Myers Squibb annual revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bristol Myers Squibb Revenue Growth & History (BMY)
Bristol Myers Squibb reported $48.19B in revenue for fiscal 2025, a decrease of 0.22% from the previous fiscal year.
View full Bristol Myers Squibb company overviewBristol Myers Squibb annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $48.19B | −$106.0M | −0.22% |
| 2024 | 2024-12-31 | $48.30B | $3.29B | +7.32% |
| 2023 | 2023-12-31 | $45.01B | −$1.15B | −2.50% |
| 2022 | 2022-12-31 | $46.16B | −$226.0M | −0.49% |
| 2021 | 2021-12-31 | $46.38B | $3.87B | +9.09% |
| 2020 | 2020-12-31 | $42.52B | $16.37B | +62.62% |
| 2019 | 2019-12-31 | $26.14B | $3.58B | +15.89% |
| 2018 | 2018-12-31 | $22.56B | $1.78B | +8.59% |
| 2017 | 2017-12-31 | $20.78B | $1.35B | +6.94% |
| 2016 | 2016-12-31 | $19.43B | $2.87B | +17.31% |
| 2015 | 2015-12-31 | $16.56B | $681.0M | +4.29% |
| 2014 | 2014-12-31 | $15.88B | −$506.0M | −3.09% |
| 2013 | 2013-12-31 | $16.39B | −$1.24B | −7.01% |
| 2012 | 2012-12-31 | $17.62B | −$3.62B | −17.05% |
| 2011 | 2011-12-31 | $21.24B | $1.76B | +9.03% |
| 2010 | 2010-12-31 | $19.48B | $676.0M | +3.59% |
| 2009 | 2009-12-31 | $18.81B | $1.09B | +6.17% |
| 2008 | 2008-12-31 | $17.71B | $2.10B | +13.43% |
| 2007 | 2007-12-31 | $15.62B | — | — |
Bristol Myers Squibb quarterly revenue
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.97B | $704.0M | +5.74% |
| Q1 2026 | 2026-03-31 | $11.49B | $288.0M | +2.57% |
| Q4 2025 | 2025-12-31 | $12.50B | $160.0M | +1.30% |
| Q3 2025 | 2025-09-30 | $12.22B | $330.0M | +2.77% |
| Q2 2025 | 2025-06-30 | $12.27B | $68.0M | +0.56% |
| Q1 2025 | 2025-03-31 | $11.20B | −$664.0M | −5.60% |
| Q4 2024 | 2024-12-31 | $12.34B | $865.0M | +7.54% |
| Q3 2024 | 2024-09-30 | $11.89B | $926.0M | +8.44% |
| Q2 2024 | 2024-06-30 | $12.20B | $975.0M | +8.69% |
| Q1 2024 | 2024-03-31 | $11.87B | $528.0M | +4.66% |
| Q4 2023 | 2023-12-31 | $11.48B | $71.0M | +0.62% |
| Q3 2023 | 2023-09-30 | $10.97B | −$252.0M | −2.25% |
| Q2 2023 | 2023-06-30 | $11.23B | −$661.0M | −5.56% |
| Q1 2023 | 2023-03-31 | $11.34B | −$311.0M | −2.67% |
| Q4 2022 | 2022-12-31 | $11.41B | −$579.0M | −4.83% |
| Q3 2022 | 2022-09-30 | $11.22B | −$406.0M | −3.49% |
| Q2 2022 | 2022-06-30 | $11.89B | $184.0M | +1.57% |
| Q1 2022 | 2022-03-31 | $11.65B | $575.0M | +5.19% |
| Q4 2021 | 2021-12-31 | $11.98B | $917.0M | +8.29% |
| Q3 2021 | 2021-09-30 | $11.62B | $1.08B | +10.28% |
| Q2 2021 | 2021-06-30 | $11.70B | $1.57B | +15.54% |
| Q1 2021 | 2021-03-31 | $11.07B | $292.0M | +2.71% |
| Q4 2020 | 2020-12-31 | $11.07B | $3.12B | +39.31% |
| Q3 2020 | 2020-09-30 | $10.54B | $4.53B | +75.46% |
| Q2 2020 | 2020-06-30 | $10.13B | $3.86B | +61.47% |
| Q1 2020 | 2020-03-31 | $10.78B | $4.86B | +82.11% |
| Q4 2019 | 2019-12-31 | $7.95B | $1.97B | +33.02% |
| Q3 2019 | 2019-09-30 | $6.01B | $316.0M | +5.55% |
| Q2 2019 | 2019-06-30 | $6.27B | $569.0M | +9.98% |
| Q1 2019 | 2019-03-31 | $5.92B | $727.0M | +14.00% |
| Q4 2018 | 2018-12-31 | $5.97B | $524.0M | +9.62% |
| Q3 2018 | 2018-09-30 | $5.69B | $437.0M | +8.32% |
| Q2 2018 | 2018-06-30 | $5.70B | $560.0M | +10.89% |
| Q1 2018 | 2018-03-31 | $5.19B | $264.0M | +5.36% |
| Q4 2017 | 2017-12-31 | $5.45B | $206.0M | +3.93% |
| Q3 2017 | 2017-09-30 | $5.25B | $332.0M | +6.75% |
| Q2 2017 | 2017-06-30 | $5.14B | $273.0M | +5.60% |
| Q1 2017 | 2017-03-31 | $4.93B | $538.0M | +12.25% |
| Q4 2016 | 2016-12-31 | $5.24B | $956.0M | +22.30% |
| Q3 2016 | 2016-09-30 | $4.92B | $853.0M | +20.96% |
| Q2 2016 | 2016-06-30 | $4.87B | $708.0M | +17.01% |
| Q1 2016 | 2016-03-31 | $4.39B | $350.0M | +8.66% |
| Q4 2015 | 2015-12-31 | $4.29B | $29.0M | +0.68% |
| Q3 2015 | 2015-09-30 | $4.07B | $148.0M | +3.77% |
| Q2 2015 | 2015-06-30 | $4.16B | $274.0M | +7.05% |
| Q1 2015 | 2015-03-31 | $4.04B | $230.0M | +6.04% |
| Q4 2014 | 2014-12-31 | $4.26B | −$183.0M | −4.12% |
| Q3 2014 | 2014-09-30 | $3.92B | −$144.0M | −3.54% |
| Q2 2014 | 2014-06-30 | $3.89B | −$159.0M | −3.93% |
| Q1 2014 | 2014-03-31 | $3.81B | −$20.0M | −0.52% |
| Q4 2013 | 2013-12-31 | $4.44B | $250.0M | +5.97% |
| Q3 2013 | 2013-09-30 | $4.07B | $329.0M | +8.81% |
| Q2 2013 | 2013-06-30 | $4.05B | −$395.0M | −8.89% |
| Q1 2013 | 2013-03-31 | $3.83B | −$1.42B | −27.04% |
| Q4 2012 | 2012-12-31 | $4.19B | −$1.26B | −23.16% |
| Q3 2012 | 2012-09-30 | $3.74B | −$1.61B | −30.10% |
| Q2 2012 | 2012-06-30 | $4.44B | −$991.0M | −18.24% |
| Q1 2012 | 2012-03-31 | $5.25B | $240.0M | +4.79% |
| Q4 2011 | 2011-12-31 | $5.45B | $343.0M | +6.71% |
| Q3 2011 | 2011-09-30 | $5.34B | $547.0M | +11.40% |
| Q2 2011 | 2011-06-30 | $5.43B | $666.0M | +13.97% |
| Q1 2011 | 2011-03-31 | $5.01B | $204.0M | +4.24% |
| Q4 2010 | 2010-12-31 | $5.11B | $78.0M | +1.55% |
| Q3 2010 | 2010-09-30 | $4.80B | $10.0M | +0.21% |
| Q2 2010 | 2010-06-30 | $4.77B | $103.0M | +2.21% |
| Q1 2010 | 2010-03-31 | $4.81B | $485.0M | +11.22% |
| Q4 2009 | 2009-12-31 | $5.03B | — | — |
| Q3 2009 | 2009-09-30 | $4.79B | −$466.0M | −8.87% |
| Q2 2009 | 2009-06-30 | $4.67B | −$538.0M | −10.34% |
| Q1 2009 | 2009-03-31 | $4.32B | — | — |
| Q3 2008 | 2008-09-30 | $5.25B | — | — |
| Q2 2008 | 2008-06-30 | $5.20B | — | — |
Bristol Myers Squibb revenue growth trends
Over the last five reported fiscal years, revenue grew from $42.52B to $48.19B, a compound annual growth rate of 2.54%. Bristol Myers Squibb's latest reported quarter, Q2 2026, generated $12.97B in revenue, an increase of 5.74% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Bristol Myers Squibb source filings ↗Community posts
Bristol Myers reports deeper myeloma responses with iberdomide regimen
Bristol Myers Squibb ($BMY) presented Phase 3 EXCALIBER-RRMM results for iberdomide combined with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. Among 420 evaluable patients, 41.1% achieved a complete response wit ...
Bristol Myers reports sustained two-year Sotyktu responses in psoriatic arthritis
Bristol Myers ($BMY) Squibb presented two-year follow-up from the POETYK PsA-2 extension study of Sotyktu in psoriatic arthritis. Among patients continuously receiving treatment, the ACR20 response rate was 76.2% using observed data and 65. ...
